The capital of the medical device industry has surged in the latest medical device on June 9, with a $5.6 billion investment in yunnan baiyao, an established pharmaceutical company. The pharmaceutical giant fosun has spun off a separate listing of medical device operations. Mindray is on the a-share market, with A market value of $100 billion. 

 

In the capital action of some enterprises, it will undoubtedly have a big impact on the competitive pattern of medical device market. 

 

Fish jump 

 

In the case of local medicine and medical devices, it is a big deal to take a stake in yunnan baiyao. Diving, as one of the medical device industry leading enterprises, its kuang-ming wu through 10 years of time, with the power of the capital, has directly or indirectly to create, with the three listed medical devices company, now also holds the diving medical and two listed Wan Dong medical machinery, diving undoubtedly has become a holding investment platform. 

 

One of the big investments that has been made in the past year was the $1.8 billion price tag of wandong medical and the armed group from China resources in 2015. 

 

Diving in November last year, also issued announcement, the proposed $863 million acquisition of Shanghai in the optimal pharmaceutical technology co., LTD. 61.62% stake, into the medical field of disinfection. 

 

In February of this year, world through its subsidiaries in Germany, the acquisition of all of German Metrax co co, this is a research and development, production and sales of the emergency medical products enterprises. 

 

Today, the fish leap will take the yunnan white medicine with 5.6 billion yuan, which is widely watched by medical devices. 

 

According to the annual report, the total revenue of the company in 2016 was 26.33 billion yuan, up 25.14 percent year on year. The net profit attributable to the non-recurring income of listed company shareholders was 489 million yuan, up 39.5 percent year on year. 

 

Fosun layout medical instruments 

 

Fosun is, in many people's eyes, a mainstream pharmaceutical company. But when guo guangchang, the chairman of fosun, first started his business, he made the first one million. 

 

After that, the company has carried on the layout in such aspects as drugs, mainly in high-quality pharmaceutical companies, including jiangsu wanbang, jinzhou Mr Leong, friends guilin pharmaceutical medicine, chongqing, shenyang red flag is the main platform for the pharmaceutical industry, such as sinopharm is the main drug distribution platform. 

 

And as the drug market enters a steady state, medical devices have become a subarea of fosun's focus. 

 

According to the annual report, in 2016, the company's operating income was 14629 million yuan, and medical devices and medical diagnostic services sold 26.64 billion yuan, accounting for 18.17 percent. And the "Da Vinci operating robot" by fosun, which has about 19,000 operations in mainland China and Hong Kong, was up about 54 percent from 2015. There are even media reports that the robot is "making 15 billion a year". 

 

As it is seen, fosun is poised for a big harvest in medical devices, and its Israeli subsidiary will soon be split up in Hong Kong. As of the end of 2015, Sisram's total assets were 16.8 billion yuan, with a net asset of 202 million yuan, the statement said. Total revenue was 685 million yuan in 2015, with a net profit of 49.36 million yuan. 

 

Sisram is fosun medicine founded in Israel in 2013, a subsidiary of that year in May, fosun medicine through Sisram bought Israel medical cosmetology instrument company Alma, at a cost of $221.63 million. Fosun is interested in advancing the company's IPO by the end of 2017. 

 

With the ipo of Alma, fosun pharmaceuticals (a-shares + H shares), China drug holdings and Alma corporation will be fosun's three listed companies in the pharmaceutical industry. 

 

Michael is hitting A shares 

 

Last year, the cypress blue machine was able to return home from the United States with a number of articles before and after returning from the United States. Today, mindray is coming to A shares, many investors are very bullish on, through the horizontal comparison, think that once listed, with its good profitability, realization of 60 times earnings is possible. 

 

In 2016, it earned a net profit of $1.734 billion. In that case, the company's market value could exceed $100 billion, making it the country's first "medical-device carrier" worth hundreds of billions of dollars. 

 

More than 10 days ago, the SEC's website disclosed that the prospectus for the ipo was disclosed. According to the document, the company intends to list on the shenzhen stock exchange and issue no more than 121.6 billion shares, accounting for no less than 10 per cent of the total equity in the offering, and the fund will raise about 6626 million yuan. 

 

Big wave drug companies march into medical devices 

 

In addition to the capital action of the three companies, many pharmaceutical companies have moved aggressively into medical devices and have an impact on the market. 

 

The company announced in September 2015 that it intends to cooperate with Siemens to set up a joint venture in guangzhou to build a medical diagnostic center. In July 2016, the broad medicine baiyun mountain and the United States medical officially signed a cooperation letter of intent, plans to set up joint venture company, investment of about 300 million yuan, in guangzhou development zone built with independent intellectual property rights of high-end medical equipment research and development production base. 

 

Conus pharmaceuticals is also moving into medical devices, and in February this year it bought 100 per cent of the business in fuzhou, the capital. In April, the company bought 100 percent of baotou medical equipment. 

 

According to the annual report, the total revenue in 2016 was 21.6 billion yuan, the medical device business was $900 million, and the medical device business grew more than 20 percent from the previous year. Kangmei is also receiving the medical and medical device hosting business of several hospitals in punning, guangdong, with annual revenue of about 5 billion yuan. 

 

The total revenue of the company in 2016 was 12.3 billion yuan. Medical equipment has grown to 18.59 billion yuan. The drug company recently teamed up with citic capital for $600 million to repurchase the company and believe there will be a bigger crop in the future of medical devices. 

 

There are more cases of pharmaceutical companies moving into medical devices. For example, the total revenue of 2016 was 615.57 billion yuan, and the medical equipment was 48.71 billion yuan. Since 2013, the company has set up a nationwide distribution of high-value consumables business, holding or building 16 medical device distribution companies. It has recently acquired stakes in 12 joint ventures in the hope of achieving a 75% majority. 

 

In addition, there are also Kantian, national medicine, Beijing keyuan credit sea, etc., all in the medical device circulation area to carry out the layout.